CY1110789T1 - Συνδυασμος παραγωγων τριαζινης και ευαισθητοποιητων ινσουλινης - Google Patents

Συνδυασμος παραγωγων τριαζινης και ευαισθητοποιητων ινσουλινης

Info

Publication number
CY1110789T1
CY1110789T1 CY20101100840T CY101100840T CY1110789T1 CY 1110789 T1 CY1110789 T1 CY 1110789T1 CY 20101100840 T CY20101100840 T CY 20101100840T CY 101100840 T CY101100840 T CY 101100840T CY 1110789 T1 CY1110789 T1 CY 1110789T1
Authority
CY
Cyprus
Prior art keywords
combination
triazine derivatives
insulin sensitizers
insulin
triazine
Prior art date
Application number
CY20101100840T
Other languages
English (en)
Inventor
Gérard Moinet
Daniel Cravo
Didier Mesangeau
Original Assignee
Poxel Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel Sas filed Critical Poxel Sas
Publication of CY1110789T1 publication Critical patent/CY1110789T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά εις συνδυασμούς παραγώγων τριαζίνης και ευαισθητοποιητών ινσουλίνης για την θεραπευτική αγωγή και/ή πρόληψη του διαβήτη και παθολογικών καταστάσεων, που συνδυάζονται με αντίσταση στην ινσουλίνη, όπου το παράγωγο τριαζίνης είναι μια ένωση του τύπου (I).
CY20101100840T 2006-01-13 2010-09-16 Συνδυασμος παραγωγων τριαζινης και ευαισθητοποιητων ινσουλινης CY1110789T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600344A FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
EP06829706A EP1971330B1 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers

Publications (1)

Publication Number Publication Date
CY1110789T1 true CY1110789T1 (el) 2015-06-10

Family

ID=36654309

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100840T CY1110789T1 (el) 2006-01-13 2010-09-16 Συνδυασμος παραγωγων τριαζινης και ευαισθητοποιητων ινσουλινης

Country Status (22)

Country Link
US (2) US8791115B2 (el)
EP (1) EP1971330B1 (el)
JP (1) JP5249782B2 (el)
KR (2) KR101482685B1 (el)
CN (1) CN101355933A (el)
AR (1) AR059032A1 (el)
AT (1) ATE476179T1 (el)
AU (1) AU2006334734B2 (el)
BR (1) BRPI0620985B8 (el)
CA (1) CA2640897C (el)
CY (1) CY1110789T1 (el)
DE (1) DE602006016014D1 (el)
DK (1) DK1971330T3 (el)
EA (1) EA015576B1 (el)
ES (1) ES2347177T3 (el)
FR (1) FR2896159B1 (el)
IL (1) IL192558A (el)
PL (1) PL1971330T3 (el)
PT (1) PT1971330E (el)
SI (1) SI1971330T1 (el)
WO (1) WO2007079917A2 (el)
ZA (1) ZA200806947B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
KR101623819B1 (ko) * 2008-12-12 2016-05-24 뽁셀 에스아에스 트리아진 유도체들과 인슐린의 조합물 및 당뇨병을 치료하기 위한 이의 용도
EP2367802B1 (en) 2008-12-12 2016-04-20 Poxel Tetrahydrotriazine compounds for treating diseases associated with ampk activity
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
KR20120011667A (ko) 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
CN111918655B (zh) 2018-06-06 2024-05-31 博希尔公司 治疗患有慢性肾脏疾病的糖尿病受试者的方法
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
FR2863484B1 (fr) * 2003-12-11 2007-04-13 Oreal Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Also Published As

Publication number Publication date
ATE476179T1 (de) 2010-08-15
CA2640897C (en) 2015-10-20
EP1971330B1 (en) 2010-08-04
DE602006016014D1 (de) 2010-09-16
BRPI0620985A2 (pt) 2011-11-29
AU2006334734B2 (en) 2012-07-19
US8791115B2 (en) 2014-07-29
KR20140033498A (ko) 2014-03-18
IL192558A (en) 2013-04-30
AR059032A1 (es) 2008-03-12
KR20080088630A (ko) 2008-10-02
FR2896159A1 (fr) 2007-07-20
PT1971330E (pt) 2010-09-09
WO2007079917A2 (en) 2007-07-19
EA200801676A1 (ru) 2008-12-30
ES2347177T3 (es) 2010-10-26
AU2006334734A1 (en) 2007-07-19
JP2009523142A (ja) 2009-06-18
CA2640897A1 (en) 2007-07-19
CN101355933A (zh) 2009-01-28
BRPI0620985B1 (pt) 2020-04-28
US20140050786A1 (en) 2014-02-20
FR2896159B1 (fr) 2008-09-12
JP5249782B2 (ja) 2013-07-31
WO2007079917A3 (en) 2007-08-30
EA015576B1 (ru) 2011-10-31
SI1971330T1 (sl) 2010-11-30
DK1971330T3 (da) 2010-10-25
BRPI0620985B8 (pt) 2021-05-25
EP1971330A2 (en) 2008-09-24
ZA200806947B (en) 2009-11-25
PL1971330T3 (pl) 2011-01-31
KR101482685B1 (ko) 2015-01-14
US20100285117A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
CY1110789T1 (el) Συνδυασμος παραγωγων τριαζινης και ευαισθητοποιητων ινσουλινης
CY1118448T1 (el) Παραγωγο δικυκλοανιλινης
CY1117078T1 (el) Παραγωγα 1-((5-ετεροαρυλθειαζολ-2-υλ) αμινοκαρβονυλ) πυρρολιδινο-2-καρβοξαμιδης ως αναστολεις φωσφατιδυλινοσιτολ 3-κινασης (ρι3κ) χρησιμα στη θεραπεια πολλαπλασιαστικων νοσων
CY1123253T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν αναστολεα του sglt2, εναν αναστολεα της dpp-iv και προαιρετικα εναν επιπλεον αντιδιαβητικο παραγοντα και χρησεις αυτης
EA201170735A1 (ru) Производные бензотиазола в качестве средств против рака
CY1123919T1 (el) 1η-βενζιμιδαζολο-4-καρβοξαμιδια υποκατεστημενα με τεταρτοταγη ανθρακα στην 2-θεση ειναι ισχυροι αναστολεις parp
CY1118526T1 (el) Παραγωγα διϋδροπυραζολοπυριμιδινονης
CY1114452T1 (el) Ενωσεις πυρρολιου
CY1120995T1 (el) Ετεροκυκλικη ενωση και χρηση αυτης
CY1116589T1 (el) Παραγωγο κυκλοπεντυλακρυλamιδιου
CY1117409T1 (el) Παραγωγα γλυκοσιδιου και η χρηση τους
CY1118650T1 (el) Παραγωγα βενζιμιδαζολιου
CY1116333T1 (el) Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr
CY1107215T1 (el) Υποκατεστημενα παραγωγα πυριδινυλιου και πυριμιδινυλιου ως διαμορφωτες του μεταβολισμου και η θεραπεια των σχετικων με αυτον διαταραχων
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
CY1109610T1 (el) Παραγωγο βενζιμιδαζολης και η χρηση αυτου ως ανταγωνιστου του υποδοχεα αιι
CY1115738T1 (el) Κρυσταλλικα επιδιαλυτωμενα συμπλοκα των παραγωγων (1s)-1,5-anyδpo-1-c-(3-((φainyλ)meθυλ) φαινυλ)-d-γλουσιτολης με αλκοολες οπως αναστολεις sglt2 για τη θεραπευτικη αντιμετωπιση του διαβητη
CY1113649T1 (el) Θεραπευτικα μεσα
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
CY1112465T1 (el) Παραγωγα αμινοτριαζολης ως αγωνιστες alx
CY1112604T1 (el) Χρηση ενος βητα αποκλειστη για την παρασκευη ενος φαρμακου για τη θεραπεια αιμαγγειωματων
CY1115744T1 (el) Παραγωγο σπειροϊμιδαζολονης
MA32505B1 (fr) 5-alcynyl-pyrimidines